miR-146a在冠状动脉粥样硬化性心脏病中的研究进展

doi:10.3969/j.issn.2095-378X.2018.03.014

Abstract

Abstract: The incidence of coronary atherosclerotic heart disease (CHD) is increasing in China, which can lead to serious and fatal complications such as myocardial infarction, heart failure, and sudden death.MiR-146a is closely related to the occurrence, development, and prognosis of CHD.It is expressed in endothelial cells, smooth muscle cells, and myocardiocytes of CHD animal models.It mainly regulates inflammatory immune response and angiogenesis by acting on related target genes and signaling pathways.MiR-146a can affect the risk factors of coronary heart disease, atherosclerotic plaque,coronary collateral circulation, ischemia-reperfusion injury, drug treatment, and so on.It can become a new target for the diagnosis and treatment of CHD.This article elaborated the relationship between miR-146a and CHD, aiming to provide a theoretical basis for clinical diagnosis, treatment, and efficacy evaluation of CHD.

Key words: miR-146a, Coronary atherosclerotic heart disease, Inflammation

CLC Number:

R 653

HUANG Haitao, ZHONG Chongjun. Research advance on miR-146a in coronary atherosclerotic heart disease[J]. Surgical Research and New Technique, 2018, 7(3): 201-205.

References

[1] Muneera K, Majeed A.Naveed AK.Comparative evaluation of Nigella sativa (Kalonji) and simvastatin for the treatment of hyperlipidemia and in the induction of hepatotoxicity[J].Pak J Pharm Sci, 2015, 28(2):493-498.
[2] van Rooij E, Olson EN.MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets[J].J Clin Invest, 2007, 117(9):2369-2376.
[3] Xu WD, Lu MM, Pan HF, et al.Association of MicroRNA-146a with autoimmune diseases[J].Inflammation, 2012, 35(4):1525-1529.
[4] Huffaker TB, Hu R, Runtsch MC, et al.Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity[J].Cell Rep, 2012, 2(6):1697-1709.
[5] Gao M, Wang X, Zhang X, et al.Attenuation of cardiac dysfunction in polymicrobial sepsis by microrna-146a is mediated via targeting of IRAK1 and TRAF6 expression[J].J Immunol, 2015, 195 (2):672-682.
[6] Seo HH, Lee SY, Lee CY, et al.Exogenous miRNA-146a enhances the therapeutic efficacy of human mesenchymal stem cells by increasing vascular endothelial growth factor secretion in the ischemia/reperfusion-injured heart[J].J Vasc Res, 2017, 54 (2):100-108.
[7] Kim YR, Hong SH.Associations of MicroRNA polymorphisms (miR-146a, miR-196a2, and miR-499) with the risk of hypertension in the Korean population[J].Genet Test Mol Bioma, 2016, 20(8):420-426.
[8] Yang ZX, Wang YZ, Jia BB, et al.Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia[J].Geriatr Gerontol Int, 2016, 16(3):322-328.
[9] Feng B, Chen S, Gordon AD, et al.miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes[J].J Mol Cell Cardiol, 2017, 105(4):70-76.
[10] Latronico MV, Catalucci D, Condorelli G.MicroRNA and cardiac pathologies[J].Physiol Genomics, 2008, 34 (3):239-242.
[11] Emadi SS, Soufi FG, Khamaneh AM, et al.MicroRNA-146a expression and its intervention in NF-кB signaling pathway in diabetic rat aorta[J].Endocr Regul, 2014, 48 (2):103-108.
[12] Eftekhar E, Doustaki Zaboli M, Katebi M, et al.MicroRNA-146a and its adapter proteins are affected by diabetes in rat’s heart[J].Bratisl Lek Listy, 2016, 117(3):166-170.
[13] Miki T, Yuda S, Kouzu H, et al.Diabetic cardiomyopathy: pathophysiology and clinical features[J].Heart Fail Rev, 2013, 18 (2):149-166.
[14] Westerink J, van der Graaf Y, Faber DR, et al.Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases[J].Eur J Prev Cardiol, 2012, 19(4):864-873.
[15] Danzi S, Klein I.Thyroid disease and the cardiovascular system[J].Endocrinol Metab Clin North Am, 2014, 43(2):517-528.
[16] Tian L, Ni J, Guo T, et al.TSH stimulates the proliferation of vascular smooth muscle cells[J].Endocrine, 2014, 46(3):651-658.
[17] Alibaz Oner F, Yurdakul S, Oner E, et al.Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism[J].Endocrine, 2011, 40(2):280-284.
[18] Cheng HS, Sivachandran N, Lau A, et al.MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways[J].EMBO Mol Med, 2013, 5(7):1017-1034.
[19] Dong S, Xiong W, Yuan J, et al.MiRNA-146a regulates the maturation and differentiation of vascular smooth muscle cells by targeting NF-κB expression[J].Mol Med Rep, 2013, 8(2):407-412.
[20] Li K, Ching D, Luk FS, et al.Apolipoprotein enhances microrna-146a in monocytes and macrophages to suppress nuclear factor-kappab-driven inflammation and atherosclerosis[J].Circ Res, 2015, 117(1):e1-e11.
[21] Vasa-Nicotera M, Chen H, Tucci P, et al.MiR-146a is modulated in human endothelial cell with aging[J].Atherosclerosis, 2011, 217(2):326-330.
[22] Wu ZW, Liu YF, Wang S, et al.miRNA-146a induces vascular smooth muscle cell apoptosis in a rat model of coronary heart disease via NF-κB pathway[J].Genet Mol Res, 2015, 14(4):18703-18712.
[23] Li J, Huang J, Dai L, et al.miR-146a, an IL-1β miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4[J].Arthritis Res Ter, 2012, 14(2):1.
[24] Zhu K, Pan Q, Zhang X, et al.MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression[J].Carcinogenesis, 2013, 34(9):2071-2079.
[25] Wang J, Yan Y, Song D, et al.Reduced plasma mir-146a is a predictor of poor coronary collateral circulation in patients with coronary artery disease[J].Biomed Res Int, 2016, 2016(7):4285942.
[26] Oerlemans MI, Mosterd A, Dekker MS, et al.Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs[J].EMBO Mol Med, 2012, 4(11):1176-1185.
[27] Wang X, Ha T, Liu L, et al.Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury[J].Cardiovasc Res, 2013, 97(3):432-442.
[28] Brudecki L, Ferguson DA, McCall CE, et al.MicroRNA-146a and RBM4 form a negative feed-forward loop that disrupts cytokine mRNA translation following TLR4 responses in human THP-1 monocytes[J].Immunol Cell Biol, 2013, 91(8):532-540.
[29] Taganov KD, Boldin MP, Chang K-J, et al.NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses[J].PNAS, 2006, 103(33):12481-12486.
[30] Huang W, Tian SS, Hang PZ, et al.Combination of microRNA-21 and microRNA-146a attenuates cardiac dys-function and apoptosis during acute myocardial infarction in mice[J].Mol Ther Nucleic Acids, 2016, 5(3):e296.
[31] Suzuki Y, Kim HW, Ashraf M, et al.Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas[J].Am J Physiol Heart Circ Physiol, 2010, 299(4):H1077-H1082.
[32] Takahashi Y, Satoh M, Minami Y, et al.Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of rennin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels[J].Clin Sci (Lond), 2010, 119(9):395-405.
[33] Hsieh JY, Huang TS, Cheng SM, et al.miR-146a-5p circuitry uncouples cell proliferation and migration, but not differen-tiation, in human mesenchymal stem cells[J].Nucleic Acids Res, 2013, 41(21):9753-9763.
[34] Perry MM, Moschos SA, Williams AE, et al.Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells[J].J Immunol, 2008, 180(8):5689-5698.

Research advance on miR-146a in coronary atherosclerotic heart disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments